Pra Health (PRAH) Stock Price & Overview

NASDAQ:PRAH

Current stock price

165.21
-2.8 (-1.67%)
At close:
166.01
+0.8 (+0.48%)
After Hours:

The current stock price of PRAH is 165.21 null. Today PRAH is down by -1.67%. In the past month the price decreased by -2.76%. In the past year, price increased by 73.81%.

PRAH Key Statistics

52-Week Range93 - 175.95
Current PRAH stock price positioned within its 52-week range.
1-Month Range164.28 - 171.07
Current PRAH stock price positioned within its 1-month range.
Market Cap
10.705B
P/E
32.65
Fwd P/E
23.77
EPS (TTM)
5.06
Dividend Yield
N/A

PRAH Stock Performance

Today
-1.67%
1 Week
-0.81%
1 Month
-2.76%
3 Months
+5.80%
Longer-term
6 Months +31.70%
1 Year +73.81%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

PRAH Stock Chart

Pra Health / PRAH Daily stock chart

PRAH Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to PRAH. When comparing the yearly performance of all stocks, PRAH is one of the better performing stocks in the market, outperforming 77.96% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PRAH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PRAH. There are concerns on the financial health of PRAH while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRAH Earnings

Next Earnings DateMar 1, 2022
Last Earnings DateN/A
PeriodQ1 / 2021
EPS Reported$1.35
Revenue Reported
EPS Surprise -0.93%
Revenue Surprise %

PRAH Forecast & Estimates

4 analysts have analysed PRAH and the average price target is 171.11 null. This implies a price increase of 3.57% is expected in the next year compared to the current price of 165.21.

For the next year, analysts expect an EPS growth of 29.21% and a revenue growth 19.32% for PRAH


Analysts
Analysts60
Price Target171.11 (3.57%)
EPS Next Y29.21%
Revenue Next Year19.32%

PRAH Groups

Sector & Classification

Index Membership

PRAH Financial Highlights

Over the last trailing twelve months PRAH reported a non-GAAP Earnings per Share(EPS) of 5.06. The EPS decreased by -1.36% compared to the year before.


Income Statements
Revenue(TTM)3.33B
Net Income(TTM)213.32M
Industry RankSector Rank
PM (TTM) 6.4%
ROA 4.98%
ROE 13.71%
Debt/Equity 0.74
Chartmill High Growth Momentum
EPS Q2Q%28.57%
Sales Q2Q%19.15%
EPS 1Y (TTM)-1.36%
Revenue 1Y (TTM)6.57%

PRAH Ownership

Ownership
Inst Owners0%
Shares64.80M
Float46.12M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About PRAH

Company Profile

PRAH logo image PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. The company is headquartered in Raleigh, North Carolina and currently employs 18,100 full-time employees. The company went IPO on 2014-11-13. The firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The firm's service offerings include product registration, strategic solutions and early development services.

Company Info

IPO: 2014-11-13

Pra Health

4130 Parklake Ave Ste 400

Raleigh NORTH CAROLINA 27612 US

CEO: Colin Shannon

Employees: 18100.0

PRAH Company Website

Phone: 19197868200.0

Pra Health / PRAH FAQ

Can you describe the business of Pra Health?

PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. The company is headquartered in Raleigh, North Carolina and currently employs 18,100 full-time employees. The company went IPO on 2014-11-13. The firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The firm's service offerings include product registration, strategic solutions and early development services.


What is the current price of PRAH stock?

The current stock price of PRAH is 165.21 null. The price decreased by -1.67% in the last trading session.


What is the dividend status of Pra Health?

PRAH does not pay a dividend.


What is the ChartMill rating of Pra Health stock?

PRAH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the valuation of Pra Health (PRAH) based on its PE ratio?

The PE ratio for Pra Health (PRAH) is 32.65. This is based on the reported non-GAAP earnings per share of 5.06 and the current share price of 165.21 null.


How many employees does Pra Health have?

Pra Health (PRAH) currently has 18100.0 employees.